Search results
Showing 1 to 13 of 13 results for psoriasis and biologics
This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS40Show all sections
Sections for QS40
- Quality statements
- Quality statement 1: Assessing disease severity
- Quality statement 2: Assessing impact of disease
- Quality statement 3: Referring to specialist services
- Quality statement 4: Assessing cardiovascular risk
- Quality statement 5: Assessing for psoriatic arthritis
- Quality statement 6: Monitoring systemic treatment
- Update information
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.
Secukinumab for treating active ankylosing spondylitis (TA407)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members
Biographies and registered interests for members of the Technology Appraisal Committee A
Biographies and registered interests for members of the Technology Appraisal Committee A
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.